Absolute Markets Insights

United States Artificial Intelligence in Diabetes Management Market Is Anticipated to Grow at a CAGR of 35.7% by 2027

Owing to rising prevalence of gestational diabetes mellitus which leads to severe complications during child birth has created a demand for treatment beyond the traditional means, says Absolute Markets Insights.

 

Pune, India -- (SBWIRE) -- 03/11/2019 -- Growing prevalence of gestational diabetes mellitus (GDM) among the pregnant women in United States ranges from 3% to 7%. Women with GDM do not continue to have hyperglycemia after delivery. However, 50% of them who have a GDM history have the risk to develop type 2 diabetes followed by their GDM diagnosis. Research & development in the artificial intelligence in diabetes management market has shown that this threat can be managed and reduced by using the right technological solutions.

Request a Sample Copy of This Report@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=186

This has created an opportunity for digital healthcare companies operating in the artificial intelligence in diabetes management market to develop a device leveraging this technology for gestational diabetes management. This solution can help expecting mothers to effectively monitor and manage their disease. In April 2018, Fujitsu in collaboration with Finnish company CleverHealth Network have announced their working on an AI-based solution which can effectively monitor and treat gestational diabetes in mothers. The mobile application is aimed to track and measure key lifestyle pattern and blood glucose data of expecting mothers. Fujitsu's data integration and modelling platform in addition will also have a user interface for data visualization that can enable healthcare professionals to recommend a treatment plan as per individual patient needs. This can track both mother and child's future health prospective. For instance, AI-enabled insights will anticipate mother's future blood glucose levels along with newborn's BMI, which will make it possible for healthcare professionals to use this data to give a targeted preventive suggestions in terms of their lifestyle and dietary choices.

"A disease that not only affects one individual but two. Can AI be a savior? The NHS has adopted a software system from Sensyne Health with the aim to help gestational diabetes. This application introduced in the artificial intelligence in diabetes management market will help to draw up predictions of both the mother's and the child's future health. The system comprises of a smartphone application that is connected to a wireless blood glucose monitor. The app has recently completed its development followed by a two year clinical evaluation in the NHS. The app is currently available to midwives and pregnant women at Royal Berkshire NHS Foundation Trust and Oxford University Hospitals NHS Foundation Trust. "

Inquiry Before Buying This Report@ https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=186

The detailed research study provides qualitative and quantitative analysis of the global artificial intelligence in diabetes management market. The market has been analyzed from demand as well as supply side. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Some of the major players operating in the global artificial intelligence in diabetes management market are Livongo Health, medicsen, Medtronic, PredictBGL, Sensyne Health plc., Apple Inc., Diabnext, DreaMed Diabetes, Ltd., Glooko Inc., GlucoMe, Google Inc., Hedia, IBM Corporation, Sweetch, TypeZero Technologies, Inc., Virta Health Corp, Wellthy Therapeutics Pvt Ltd, XBIRD among others.

By Techniques
o Cased Based Reasoning
o Machine Learning & Deep Learning
o Artificial Neural Network
o Others

By Application
o Automated Retinal Screening
o Clinical Decision Support
o Predictive Population Risk Stratification
o Patient Self-Management Tools
o Others

By Device
o Glucose Monitoring Devices
o Diagnostic Devices
o Insulin Delivery Devices
o Others

By End User
o Hospitals and Clinics
o Diabetes Management Centers
o Research Institutes

By Geography
o North America
o U.S.
o Canada
o Mexico
o Rest of North America
o Europe
o France
o The UK
o Spain
o Germany
o Italy
o Nordic Countries
? Denmark
? Finland
? Iceland
? Sweden
? Norway
o Benelux Union
? Belgium
? The Netherlands
? Luxembourg
o Rest of Europe
o Asia Pacific
o China
o Japan
o India
o Southeast Asia
? Indonesia
? Thailand
? Malaysia
? Singapore
? Rest of Southeast Asia
o Australia
o South Korea
o New Zealand
o Rest of Asia Pacific
o Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest of Middle East & Africa
o Latin America
o Brazil
o Argentina
o Rest of Latin America

Request for Customized Report@ https://www.absolutemarketsinsights.com/request_for_customization.php?id=186